Inflammation and breast cancer - Inflammatory component of mammary carcinogenesis in ErbB2 transgenic mice

被引：31

作者：

Calogero, Raffaele Adolfo ^{[1
]}

Cordero, Francesca ^{[1
]}

Forni, Guido ^{[1
]}

Cavallo, Federica ^{[1
]}

机构：

[1] Ctr Mol Biotechnol, Dept Clin & Biol Sci, I-10126 Turin, Italy

来源：

BREAST CANCER RESEARCH | 2007年 / 9卷 / 04期

关键词：

D O I：

10.1186/bcr1745

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This review addresses genes differentially expressed in the mammary gland transcriptome during the progression of mammary carcinogenesis in BALB/c mice that are transgenic for the rat neu ( ERBB2, or HER-2/neu) oncogene ( BALB-neuT(664V-E) mice). The Ingenuity knowledge database was used to characterize four functional association networks whose hub genes are directly linked to inflammation ( specifically, the genes encoding IL-1 beta, tumour necrosis factor, interferon-gamma and monocyte chemoattractant protein-1/CC chemokine ligand-2) and are increasingly expressed during such progression. In silico meta-analysis in a human breast cancer dataset suggests that proinflammatory activation in the mammary glands of these mice reflects a general pattern of human breast cancer.

引用

页数：9

共 45 条

[1]

ALLIONE A, 1994, CANCER RES, V54, P6022

[2] Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance [J].

Ambrosino, Elena ;

Spadaro, Michela ;

Iezzi, Manuela ;

Curcio, Claudia ;

Forni, Guido ;

Musiani, Piero ;

Wei, Wei-Zen ;

Cavallo, Federica .

CANCER RESEARCH, 2006, 66 (15) :7734-7740

[3] Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario [J].

Astolfi, A ;

Rolla, S ;

Nanni, P ;

Quaglino, E ;

De Giovanni, C ;

Iezzi, M ;

Musiani, P ;

Forni, G ;

Lollini, PL ;

Cavallo, F ;

Calogero, RA .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (06) :599-610

[4] Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma [J].

Astolfi, A ;

Landuzzi, L ;

Nicoletti, G ;

De Giovanni, C ;

Croci, S ;

Palladini, A ;

Ferrini, S ;

Iezzi, M ;

Musiani, P ;

Cavallo, F ;

Forni, G ;

Nanni, P ;

Lollini, PL .

AMERICAN JOURNAL OF PATHOLOGY, 2005, 166 (04) :1205-1216

[5] High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 [J].

Atkins, MB ;

Lotze, MT ;

Dutcher, JP ;

Fisher, RI ;

Weiss, G ;

Margolin, K ;

Abrams, J ;

Sznol, M ;

Parkinson, D ;

Hawkins, M ;

Paradise, C ;

Kunkel, L ;

Rosenberg, SA .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2105-2116

[6] Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of HER-2/neu transgenic mice [J].

Boggio, K ;

Nicoletti, G ;

Di Carlo, E ;

Cavallo, F ;

Landuzzi, L ;

Melani, C ;

Giovarelli, M ;

Rossi, I ;

Nanni, P ;

De Giovanni, C ;

Bouchard, P ;

Wolf, S ;

Modesti, A ;

Musiani, P ;

Lollini, PL ;

Colombo, MP ;

Forni, G .

JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (03) :589-596

[7]

BOSCO M, 1990, J IMMUNOL, V145, P3136

[8] An integrated approach of immunogenomics and bioinformatics to identify new Tumor Associated Antigens (TAA) for mammary cancer immunological prevention [J].

Cavallo, F ;

Astolfi, A ;

Iezzi, M ;

Cordero, F ;

Lollini, PL ;

Forni, G ;

Calogero, R .

BMC BIOINFORMATICS, 2005, 6 (Suppl 4)

[9]

CAVALLO F, 1992, J IMMUNOL, V149, P3627

[10] Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12 [J].

Cavallo, F ;

Signorelli, P ;

Giovarelli, M ;

Musiani, P ;

Modesti, A ;

Brunda, MJ ;

Colombo, MP ;

Forni, G .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (14) :1049-1058

← 1 2 3 4 5 →